JonesTrading analyst Justin Walsh has maintained their bullish stance on RAPP stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Justin Walsh has given his Buy rating due to a combination of factors surrounding Rapport Therapeutics, Inc. A key element is the anticipated topline data readout from the Phase IIa trial of RAP-219 in refractory focal epilepsy, expected in September 2025. This data is likely to provide early clinical validation for RAP-219, which could significantly boost interest and momentum for the company.
Additionally, the company’s focus on RAP technology and biomarker-informed trial design is expected to create a robust pipeline that can drive long-term value. The potential for RAP technology to be clinically effective and commercially competitive in multiple central nervous system indications further supports the Buy rating. The upcoming developments in their bipolar mania and diabetic peripheral neuropathic pain programs also contribute to the positive outlook for the company’s stock.
According to TipRanks, Walsh is an analyst with an average return of -3.9% and a 31.50% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Y-Mabs Therapeutics, and Bioline RX Ltd Sponsored ADR.
In another report released yesterday, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $31.00 price target.